BioSpace News Archive

PTC Therapeutics, Inc. announced that the company will host a webcast conference call to report its fourth quarter and full year 2023 financial results and provide an update on the company’s business and outlook on Thursday, Feb. 29, at 4:30 p.m. EST.

AMO Pharma Limited announced a collaboration with Population Health Research Institute, a joint institute of McMaster University and Hamilton Health Sciences in Canada, to advance a clinical proof of concept trial to assess the efficacy of AMO-02, AMO Pharma’s investigational oral glycogen synthase kinase 3 beta inhibitor, in the treatment of genotype positive arrhythmogenic cardiomyopathy.

CEL-SCI Corporation reported financial results for the quarter ended December 31, 2023, as well as key recent clinical and corporate developments.

Enalare Therapeutics Inc. announced the publication of a respiratory depression study with its lead compound, ENA-001 in the journal Anesthesiology.

EnLiSense CCM, a pioneer in non-invasive sweat-sensor technology for real-time health monitoring, is thrilled to announce a groundbreaking advancement in the world of Inflammatory Bowel Disease management.

Ensysce Biosciences, Inc. announced online publication of its manuscript entitled, “Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin® in a multi-ascending dose study with a bioequivalence arm in healthy volunteers” published online by the open-access medical journal Clinical and Translational Science sponsored by the American Society of Clinical Pharmacology and Therapeutics.

G1 Therapeutics, Inc., a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the fourth quarter and full year 2023 on Wednesday February 28, 2024, at 8:30 a.m. ET.

Lantern Pharma Inc. announced an important milestone in its antibody-drug conjugate program.

Lexaria Bioscience Corp. announced that it has entered into definitive agreements for the purchase and sale of 1,558,443 shares of common stock at a purchase price of $2.31 per share in a registered direct offering priced at-the-market under Nasdaq rules.

Vericel Corporation, a leader in advanced therapies for the sports medicine and severe burn care markets, announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024.